IASO Bio to Present Promising Findings on Equecabtagene Autoleucel for Multiple Sclerosis at both ANA and ECTRIMS 2025
SHANGHAI, NANJING, and Pleasanton, CA., September 12, 2025 - IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced promising results of its independently developed fully human anti-BCMA CAR-T cell therapy Equecabtagene Autoleucel (Eque-cel), for the treatment of Progressive Multiple Sclerosis (PMS), will be presented at the 2025 American Neurological Association (ANA) Annual Meeting and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress. The data will be disclosed through a poster presentation and an oral presentation respectively at these two premier academic conferences.
Meeting name: 2025 American Neurological Association (ANA) Annual Meeting
Type: Poster
Location:Baltimore, USA
Time: September 15, 2025
Abstract ID: M110
Meeting name: 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress
Type:Oral
Location: Barcelona, Spain
Time: September 26, 2025
Abstract ID: ECTRIMS25-1626
Presenter: Prof. Chuan Qin, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
This presentation is based on findings from an investigator-initiated trial (IIT, NCT04561557) led by Professor Wei Wang's team from the Department of Neurology at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, which aims to evaluate the efficacy and safety of Equecabtagene Autoleucel in the treatment of relapsed/refractory antibody-mediated idiopathic inflammatory disorders of the nervous system.
This study enrolled five patients with PMS，including 1 with primary progressive MS (PPMS) and 4 with secondary progressive MS (SPMS).
Efficacy
- The mean Expanded Disability Status Scale（EDSS）score improved from 6.2 at baseline to 5.0 at the last Visit;
- The mean 9-HPT times decreased from 51.3 (left) and 40.9 seconds (right) to 35.9 and 27.8 seconds, respectively;
- The mean T25-FW times decreased from 27.3 seconds to 15.7 seconds;
- MRI revealed no new or enlarged T1 gadolinium-enhancing lesions or T2 hyperintense lesions in any of the patients.
Safety
- Four of five patients experienced transient grade 1 CRS;
- No ICANS or other neurologic toxic effects were observed post infusion;
- Only grade ≥3 neutropenia and lymphocyte count decreased were observed, with no occurrences of grade ≥3 anemia or thrombocytopenia.
Conclusion: Anti-BCMA CAR T cells are well tolerated and highly effective in treating progressive MS, demonstrated by the improvement in physical function and the resolution of OCBs and kappa free light chains in CSF.
About Equecabtagene Autoleucel（Eque-cel）
Equecabtagene Autoleucel（Eque-cel） is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations,Eque-cel demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve higher and deeper responses.
